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Summary and Conclusions
A systematic discussion of the results is given belorv in analogy with the aims and outline of
this thesis presented in chapter l.
Part I: Insulin and insulin resistance: effects on plasma cholesteryl ester transfer and
cholesterol esterification, lecithin:cholesterol acyltransferase and lipid transfer protein
activities.
In chapter 2 to 8 the influences of NIDDM and insulin resistance on plasma cholesteryl ester
transÍèr (CE1') and cholesterol esterification (EST) as well as on lecithin:cholesterol acyl-
transferase (LCAT) and lipid transfer protein activíties, (CETP and PLTP), measured with
excess exogenous substrate, are described. Several interventions are perÍbrmed to evaluate
the eÍ'fect of manipulation in plasma free fatty acids (FFA) and triglycerides on plasma CET
and EST as well as on the plasma activity levels of LCAT, CETP and PLTP.
In Chapter 2, plasma CET and EST were compared between l6 normo- and moderately
dyslipidaemic NIDDM men and 16 matched healthy men. Furthermore, we investigated
rvhether plasma activity levels of LCAT, CETP and PLTP contribute to plasma CET and EST
in conjunction with plasma levels of apolipoprotein (apo) B-containing lipoproteins. Plasma
CET, EST, LCAT and PLTP activity levels were higher in conjunction with higher plasma
triglycerides, and Iower HDL cholesterol and HDL cholesteryl ester levels in NIDDM. Plasma
CETP activity as well as lipoprotein lipase and hepatic lipase activities were not different in
NIDDM compared to healthy subjects. ln the subgroup ol nonnotriglyceridaemic NIDDM
patients (plasma triglycerides <2 0 mmol/l), no differences in plasma CET, EST, as well as in
LCAT and PLTP activity were observed. Multiple stepwise regression analysis dernonstrated
that CET was positively related to VLDL+LDL cholesterol, plasma triglycerides, PLTP
activity and CETP activity, whereas the diabetic state had no effect on plasma CE'f, indepen-
dently from these parameters. HDL cholesteryl ester was negatively related to plasma CET,
hepatrc lipase activity and NIDDM and positively to plasma LCAT activity. From this study
we concluded that the elevated plasma CET in plasma from NIDDM patients is associated
with higher plasma triglycerides and PLTP activity levels. FurtheÍrnore, a high plasma CET
may provide a mechanism contributing to low HDL cholesterol in NIDDM.
Chapter 3 reports on the effects of exogenous hyperinsulinaemia on plasma CET and ESI
in norrnotriglyceridaemic NIDDM patients and individually rnatched healthy sublects during
a 2 step hyperinsulinaemic euglycaemic clamp over 6-7 hours (30 mUkglh and 150
rnU/kg/h), in vierv of the plasma CET and EST increasing effects of the plasma triglyceride
concentration and the expected lorvering of triglycerides by insulin. No betr.veen goup
dif-ferences in baseline plasma triglycerides were observed, but the HDL cholesteryl ester
content was lower and the HDL triglyceride content was higher in diabetic patients. Baseline
plasma CET and EST were similar in the groups. lnsulin rnfusion decreased plasma CET
similarly in both goups in conjunction with a fall in triglycerides cornpared to saline infusi-
on. The insulin-induced change in plasma EST was not different from that during saline
ínfusion. These findings indicate that acute hyperinsulinaemia has a different effect on these
processes involved in HDL rnetabolism. Despite unaltered fasting plasma CET, HDL core
lipid composition was abnormal in diabetic patients, suggesting that appart from the choleste-
rvl ester transfèr process additional mechanisms may contribute to changes in HDL metabo-
';'ï'ïilïo,"JilïïiÏïïr"",s 
of acure ndogenous t'yp"rinrutinu",n,u on"ptasma cErp and
PLTP activity. as well as on FFA, lipid and lipoproteins levels were assessed in 8 healthymen
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during a 3-h h1'perglvcaernic clamp and compared rvjth the changes of the parameters in
another group of 7 healthy men receiving an infusion ol'an eclual volurne oÍ'saline. Plasma
cholesterol and triglyceride concentrations were decreased cornpared to the minor changes
observed uring saline infusion. Plasma CETIr activity levels did not change, rvhereas plasrna
PLTP activity levels decreased signiÍicantly aÍier 2 and 3 h of hvperglvcaernia-induced
hyperinsulinaernia. The mean percentage decreasc in PLTP activity' during endogenous
hyperinsulinaemia was greater than the unchanged PI-TP activity during salrne infusion.
Plasma PLTP activity during the clamp rvas correlated negativell,rvilh the insulin sensitivity
index It rvas concluded that acuÍe hyperglycaernia-induced hyperinsulinaemia lou,ers plasrna
PLTP, but not CEï'P activity levels, either directly or coupled to et-Íccts <-rn the metabolisrn of
trr glvceride-rich I ipoprotei ns
In Chapter 5, we detennined the association of plasrna CE fP and Pl,l 'P activi l ies rvith
insulin resistance- plasma triglycerides and I.FA and assessed the l ipid translèr protein res-
ponse to insulin during a ó-7 h hyperinsulinaenric euglvcacnric clarnp (30 rrrUikgrh and 150
ntU/kgih1 in non-obese and obese healthy subjects and NIDDM patients (n..8 per uroup).
Plastna t '}LTP activitv rvas higher in obese hcalthy subjects and obese NII)DM patients
compared to non-obese healthl ' sub.jects and rvas positivcly correlated u,ith insulin resistancc',
baseline plasma lriglyceri<le and FFA. In non-obcse healthv subjccts, insulin decreased
plasrna triglycerides and increased the tlDL choÍcsten'l csteritriglvceride ratio lrr this group.
plasrna PI.TP actrvity l-cll by l1% at the cnd of the clamp, rvhich rvas significantly difïèrent
Íiom the change ivith saline. In contrast. plasma C--ElP activilv did not change cornpared to
seline intusion. The decrease in piasrna FFA, trigly'ccrjdes and P[-TP actrvity and the risc in
IIDI- cholesteryl estentrigll,ceride ratio rvere signiÍicantl1"snraller in obcse NIDDM palients.
Baselinr: I-lDl- cholestervl ester/lrrglyceride ratio rvas negatively correlated rvith plasrna
t l tg lvcer rdes  and f ' } l - ' fP  ac l i v i t r ,  bu t  no l  rv r th  C lE ' l 'P  ac t j r i t t , .  [ - rko l i se ,  the  r i se  in  ] lDL cho les-
tt:ryI ester/triglyceride ratio durirg the clarnp was relaled b thc fàll in plasrna trrglvcericlc.s
and in plasrna Pl,l- l) activrty. Wc concluded that hrgh plasrna l)l- ' ftr) actit ' i tv rs assocrate<i n. lhjnsLrlin resistancc rn coniunction wrlh altcred I '- l 'A and triglyceridr: rnela[r"rl isrn. ] l ig,h plasma
trtglycerides and Pl-l ' l) activitt, inav thrrs havc coordrnate i lècts on FIIl l , rne!abolrsm.
Chapter  6 repons the eÍ - iccts  of  24 h h1 per insul inaernia (30rnLj , 'kg/h)und o l ' thc ant i l rpr ' ; l r , -
ttc agent Acrpirnox (2-5() rng per4 h) on plasrna lrpids as rvell as on plasrna CFfl) itnd l ' j l . ' l ' l)
activity levels in 8 heallhy sub.lects and 8 NIDDM patients '[ 'his studv was perlbnrled ro
erautine whether the acute ef-Èct ol ' irrsulin on piasrra PL-l ' lJ activitv as dcscribed in chaptcr.i
and 5 lvere sustained over a proklnged period and whether P[.lP activitr, lolvcring could also
bc achieved rvhen plasnra FFA avail ibil i ty rvas decreased by inhibit ion oÍ' adipose tissue
lipolysis. Afier24 h of insulin plasma FFA, HDL choleslerol and plasma apo AI decreased rn
hcalthy subjects and in NIDDM patients The change in plasrna triglvcerides was not signifi-
cant in either group. Afier 24 h olAcipimox all these pararxetsrs. including plasrna triglvccri-
des, decreased in both groups. Insulin decreased plasma Pl,l 'P activity b1, I 7.6 ?o afier 24 h in
healthy subjects and by 10.2 yo in NIDDM patients. ' l 'he fàll in PLTP activitv in healthy
subjects rvas larger compared to that in NIDDM patients. Acipimox lorvercd Pl-' l  P activity by
l0 3To tn healthy sublects and similarl l by I 1.3% in drabetrc patients. When insulin was
inÍused for 3 h after Acipimox, a further decrease rvas fbund onl1, in healthv sub.jects. Plasma
CETP activity decreased by 9 -5026 aÍïer 24 h of insulin only in healthv subjects, but nol in
diabetic patients. Acipimox did not decrease plasrna Cll ' l 'P actrvitv in either group. ln healthy
subiects, the PLTP responses rvith insulin and Acipirno\ werc larger than the changes in
L--E'IP activity. l 'hese Íindings again suggest that there is a rnetabolrc l ink betrveen the regula-
tion of plasrna FFA and PLTP, bu1 not CEI-P. Furthennore, it rvas shorvn that the plasma
PLTP resnonse to insul in  is  b lunted in  NIDI)M.
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ln Chapter 7, the efÍèct of a large, 24 h inÍravenous fat load (artificíal triglyceride emulsi-
on, Lipofundinr{), without and with concomitant insulin infusion on plasma lipids and FFA as
rvell as on plasma LCAT, PLTP and CETP activity levels was studied in 8 healthy men, with
one week between the study days. During LipofundinR plasma trrglycerrdes and FFA strongly
increased, whereas HDL cholesterol decreased. Plasma LCAT and P[-TP activity increased,
but CETP activity remained unchanged. Concomitant insulin infusion blunted the increase in
plasma LCAT activity, but not that in PLTP activity. One week alier the first fat load plasma
non-HDL cholesterol and triglycerides were increased, whereas HDL cholesterol rvas decrea-
sed. At this time point, plasma CETP and PLTP activity levels were increased, whereas
LCAT activity was unaltered. It is concluded that plasma LCAT and PLTP activity levels are
acutely stimulated by a large intravenous fat load and that there is a delayed CETP response.
Thus, while lowering of plasma FFA availabil ity by insulin and Acipimox decreases
plasma PLTP activity as shown in chapter 5 and 6, increasing plasma FFA availability as
shown in chapter 7 stimulates plasma PLTP activity. These findings are in support of the
concept hat plasma FFA, triglycerides and PLTP activity are coordinately regulated.
In Chapter 8, the influence of insulin sensitivity and of the TaqIB CETP gene poly-
rnorphism (BlB2) on plasma LCAT, CETP and PLTP activities and their responses to hyper-
insulinaemia was studied. The effect of insulin sensitivity on l ipoprotern and hepatic l ipase
activities was also evaluated. Thirty-two non-diabetic men without severe hyperlipidaemia
rverediv idedinquart i lesofh igh(Q,) to low (Q.r) insul insensi t iv i ty .Plasmatota l  cholestero l ,
very lorv+lorv density lipoprotein cholesterol, triglycerides, and apo B were higher in Qo
compared to Q,, rvhereas HDL cholesterol and apo Al rvere lowest in Qo. Plasma LCAT
activity was higher in Q., than in Q, and plasma PLTP activity was higher in Q., than in Q,
Furthermore in the combined quartiles with the lowest insulin sensitivity (Q,+Qo), baseline
plasrna PLTP activity was higher than in the combined quartiles with the highest sensitivity
(Q,+Qr) lnsulin sensitivity did not influence plasma CETP activity. Postheparin plasma
lipoprotein lipase activity was highest and hepatic lipase activity rvas lowest in Q,. Insulin
infusion decreased plasma PLTP activity in all groups. The CETP genotype ererted no
consistent eÍ'Ècts on baseline plasma lipoproteins and LCAT, CETP and PLTP activities. The
decrease in plasma PLI'P activity after insulin was larger in B lB I than in B2B2 homozygotes.
These data show that insulin sensitivity influences plasma LCAT, PLTP, lipoprotein lipase
and hepatic lipase activities in men without diabetes. High levels of PLI'P, LCAT and hepatic
lipase in association with insulin resistance could be involved in an antiatherogenrc mecha-
nism, since these fàctors may enhance reverse cholesterol transport. Moreover, in view of the
postulated eÍïect of PLI'P to enhance reverse cholesterol transport, the 'l'aqlB CETP gene
polymorphism-related effect on the plasrna PLTP activity response to insulin could be impli-
cated in variation in atherosclerosis development associated with this genetic polymorphism.
Part II: Effects of genetic and environmental factors on high density lipoprotein choles-
terol
Numerous epidemiological studies have shown a strong inverse relationship between serum
HDI- cholesterol and nsk of coronary heart disease. Genetic, metabolic and environmental
Íàctors influence HDL cholesterol level. In this part, some genetic and environmental aspects
of HDL regulation are studied.
In chapter 9, the effect of the TaqlB CETP gene polymorphism on HDL cholesterol levels
and on the lipoprotein response to a linoleic acid-enriched, low-cholesterol diet rvas studied
in IDDM patients. HDL cholesterol was higher in B2B2 individuals than in BlBl homozygo-
tes. Afler adjustment for triglycerides and smoking, HDL cholesterol was 0.19 mmol/l higher
for each 82 allele presenl, an effect rvhich is larger than that previously obsen'ed in non-
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diabetic individuals. Plasma L--ETP activitl levels rvere not signiÍ'icantly difÍèrent betrveen
CETP genotypes. BlBl homozygotes had a nore favourable l ipoprotein response to a l inoleic
acid-enriched, Iow-cholesterol diet than Bll32 heterozygotes. Thus, the'faqlB gene poly-
morphisrn appears to be a strong determinant of HDL cholesterol in IDDM and rnay be a
detenninant ofthe lipoprotein response to a cholesterol-lorvering diet.
In chapter 10, the eÍlect of moderate alcohol consumption, the CE'fP gene polymorphism
and clinical variables was evaluated on the HDI- cholesterol concentratron and other l ipopro-
tein parameters. Thirteen moderately alcohol consuming IDDM men and l3 abstainers with
IDDM, individually matched for the CETP gene polymorphisrn, age, diabetes duration, body
mass index, smoking and presence of microaltruminuria" rvere studied. No signiÍicant di1Íe-
rences in I{DL cholesterol, serurn apo Al, serum CETP activity levels and in apo B-containing
lipoproteins were observed. Multiple regression analysis showed that HDt, cholesterol was
positively associated with the presence of the 82 allele and negatively with smoking, but not
rvith alcohol consumption. Frorn this study rve concluded that rnoderate alcohol consurxption
has no beneficial efÍèct on the lipoprotein proÍile in IDDM men. HDl, cholesterol is adverselv
influenced by smoking, whereas considerable variation in its level appears to be explained by
the CETP gene polymorphism.
In chapter l l . we investigated rvhether altered plasma activity levels of [-CAT, CEI'P and
PLTP contribute to the increase in HDt, cholesterol associated with moderate alcohol con-
surrption. Plasma LCAI-, CETP and PL'|P activity levels, as well as Iipids were measured in
alcohol-abstaining men, in men who used -. I and in rnen rvho used >l alcohol-containing
drinks per day. No drfÍèrences in plasma LCAT. CETP and PLTP activity levels were obser-
ved between the three groups, whereas the use of alcohol was associated with higher IlDt-
cholesterol. In multiple regression analysis, it was found that HDL cholesteryl ester was
positively related to alcohol intake, independently of plasrna LCAI', CETP and PLTP activity
and plasnra triglycerides. We, thereÍbre, concluded that the higher HDL cholesterol associa-
ted with moderate alcohol consumption in healthy men is unlikelv to be caused by an elïèct
on plasma LCAT, CETP arrd PL'I'P activity levels.
Part III: EfÍ 'ects of acute and chronic hyperinsulinaemia on l ipoprotein(a)
Lipoprotein(a) (Lp(a)) is an LDL-Iike particle that consists of l ipids, apo B and apo(a). l.p(a)
may be metabolized differently from triglyceride-rich lipoproteins. High plasma l-p(a) levels
are considered to be a risk factor for cardiovascular disease.
ln chapter 12, we investigated the response ofplasma tnglycerides, cholesterol, apo B and
Lp(a) to 3 h hyperglycaemia-induced hvperinsulinaemia in l6 healthy subjects (eight women
and eight men). In a control experiment saline was infused in another group of seven men.
Compared to saline inÍusion, plasma triglycerides, cholesterol and apo B decreased signiti-
cantly after 3 h hyperinsulinaemia, whereas in the entire group Lp(a) remained unchanged. Of
interest, in a subgroup of subjects with the lowest first phase insulin secretion in response to
hyperglycaemia plasma Lp(a) increased. The percent change in apo B exceeded the percent
change in Lp(a) during hyperinsulinaemia. These data support the hypothesis that Lp(a) is
metabol ized di fferently from tri glyceride-rich Iipoprotei ns.
ln chapter 13, we evaluated the responses of plasma cholesterol, triglycerides, apo B and
Lp(a) during 24 h insulin inÍusion in 6 healthy men. This experiment was necessary because
of the long half life of circulating Lp(a). Plasma total cholesterol, triglycerides and apo B
levels were decreased by insulin. In contrast, no decrease in plasrna Lp(a) was observed, and
r the percent change in apoB was different from that in Lp(a). We concluded that rnoderate
I hyperinsulinaemia has a different effect on the rnetabolism of triglyceride-rich Iipoproteins
compared to Lp(a)
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Part IV: Free fatty acid metabolism in NTDDM and obesity
Increased FFA availabilitv is thought to play an irnportant role in the pathogenesis of
hypertriglyceridaemia nd insulin resistance of glucose rnetabolisrn as observed in glucose
intolerant states. Using prolonged infusion of radiolabelled palmitate to lrace plasma FFA and
applying equilibrium tracer conditions, it has been documented that the efÍèct of insulin to
suppress the rate of appearance of plasma FFA is irnpaired in NIDDM. These findings are
generally interpreted to indicate impaired ínsulin mediated suppression of lipolysis. In appa-
rent contÍadiction with this view several in vitxt studies have demonstrated that the effect of
insulin on adipose tissue lipolysis is unimpaired in NIDDM (and obesity).
ln chapter 14, a new method is described to estimate FFA kinetic parameters using l0 min
rnÍusion of [ '"C]-pahnitate i.e non-equil ibrium tracer conditions, and a cornparison was made
with ó0 min infusion of [ ' 'C]-pahnitate i.e. during equil ibriuur tracer conditions. Ít rvas shorvn
that FFA kinetic parameters can be estimated with sutïcient precision using non-equil ibrium
data frorn short-term labelled palmitate inÍusion. Moreover, this study reemphasized the rapid
recirculation of label derived from intravascular hydrolysis of esteriÍled fatty acids that
escape frorn tissue uptake. By using non-equil ibrium tracer conditions underestimation of
FFA inÍlow because oi label recirculation fronr intravascular hydrolysis of labelled esteried
tàtty acids is prevented. Furtherrnore, the reduced radiaton dose enables repeated short
infusion studies in the same individual rvithin a short period.
In chapter 15, we evaluated the effèct ofa moderate and a high degree ofhyperinsulinae-
mia (euglycaernic clarnp with insulin infused at 30 and 150 mUrkg/h during 3 h) on FFA
kinetics in non-obese and obese healthy subjects and NIDDM patients (10 per group), based
on the method using non-equilibrium tracer conditions, described in the preceeding chapter.
A model rvas provided to estimate the contributions of the net raÍe of lipolysis (RL) and of the
rate ofappearance ofFFA that escape Íiorn tissue uptake (ESC) aÍïer intravascular triglyceri-
de hydrol,vsis to the total arterial plasrna rate of appearance (TR") during postabsorptive and
hyperinsulinaemic ircurnstances. The rnodel was based on the assumptions that transmem-
brane FFA transport is a facilitate<l process that Íbllows Michaelis-Menten kinetics. that
intravascular triglyceride hydrolysis is proportional to lipoprotein lipase activitt, and that the
plasma triglyceride concentration can be used as the substrate concentration lbr I-PL action.
'fR, 
was lower in non-obese healthy subjects compared to the other groups at lorv rnsulin
inÍusion and compared to obese NIDDM patients at high insulin inlusion. Plasma triglyceri-
des were also lower in non-obese healthy subjects during hyperinsulinaernia. Employing the
rnodel, ESC decreased significantly in each group during hyperinsulinaemia, but remained
higher in obese NIDDM patients. In contrast, RL was not diff'erent between the groups at
baseline, and its decline during hyperinsulinaernia was similar in all groups In multiple
regression analysis, total body FFA disposal was inversely related to whole body glucose
disposal during hyperinsulinaemia, whereas RL rvas unrelated to glucose disposal, NIDDM
and obesity. fhis study thus challenges the generally held contention that the anti l ipoll,t ic
eÍfect of insulin is impaired in N[DDM. We suggest that a high plasma triglyceride level
causes a higher escape of F!-A Íiom tissue uptake, leading to an impaired suppression of TR,
during a low degree of hyperinsulinaernia in NIDDM and ollese subjects, and even during a
high degree of hyperinsulinaemia rn obese NIDDM patients.
Future directions
The experirnents performed in this thesis (part I) have consistently demonstrated that there
is a metabolic l ink betrveen the reculation of olasnra FFA and triÍr lvcerides on the one hand
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and plasma PLTP but not CETP on the other hand fhus, (obese) NIDDM patients and insulin
resistant individuals without diabetes have high plasma PL1-P activity levels in conjunction
with high plasma triglycerides. Further studies are necessary to elucidate rvhich tissues
contribute to PLTP in human plasma and how PLTP secretion and catabolism is regulated at
the molecular level. Liver and adipose tissue are possible sources of plasma PLTP. The efïect
of insulin to decrease hepatic VLDL secretion has been recently demonstrated to be impaired
in NIDDM. In this thesis (part IV) it has been shown that the inhibitory effect of insulin on
adipose tissue lipolysis is not irnpaired in NIDDM. It rnay, therefore, be speculated that the
blunted plasma PLTP lowering by insulin in NIDDM (part I) is related to a diminished effect
ofinsulin in the l iver.
PLTP is now recognized to exert many Íunctions in lipoprotein metabolism. PLTP is able
to convert HDL in smaller and larger lipoprotein particles and to prolnote cellular cholesterol
efflux. Moreover, PLTP enhances the CETP-mediated cholesteryl ester transÍèr Íiom HDL to
VLDL and LDL, and increases free cholesterol transfer between lipoproteins. PLTP is able to
deliver vitamin E to endothelial cells, thereby indirectly protecting endothelial cells from
oxidative damage. The current view is, therefore, that PLI'P has predominantly antiatheroge-
nic properties. It is hypothesized that a high plasma PLTP activity level in insulin resistant
conditions (part l) may represent an antiatherosclerotic defense rnechanism. This hypothesis
can be tested in vitro by evaluating the efïèct of variation in plasrna PLTP on cellular choles-
terol efflux. Epidemiological studies are required to evaluate the inÍluence oÍ'the plasma
PLTP level on cardiovascular risk.
The effect of variation in the CETP gene on the plasrna PLTP (and CETP) response to
insulin (part I) may represent a mechanisrr responsible for the effect of the CETP gene
polymorphism on atherosclerosis development. Moreover, the efÍèct of the CETP gene
polymorphism on HDL cholesterol and the lipoprotein response to a cholesterol lowering diet
(part ll) is likely to provide a tool Íbr the clinician to target interventions 1o those subjects
who will have the most benefit. If future studies demonstrate that the lipid lowering efÍèct of
pharmacological intervention is also dependent on this genetic polymorphism, then such a
pharmacogenomic approach rvould considerably increase cost ef'Íectiveness in primary and
secondary preventiol.l of cardiovascular disease.
Finally, it should be emphasized that the process of cholesteryl ester transÍèr whereby
cholesteryl esters are transfened from HDL to VLDL and LDL is still regarded as a two edged
swoard. Thus, an increased cholesteryl ester transfer will decrease the HDL cholesteryl ester
content and will increase the cholesteryl ester concentration in VLDL and LDL. l'he effect of
this process on development ofatherosclerosis is likely to be dependent on the eÍïcacy ofthe
non-HDL compared to the HDL route for cholesterol delivery to the liver. When hepatic
VLDL and LDL removal is slow this process is probably atherogenic. When hepatic HDL
cholesterol uptake is not very efficient, this process may provide a protective alternative route
for cholesterol delivery to the liver. As yet it is difÍlcult to predict the eÍfect of CETP-targeted
interventions on cardiovascular p otection.
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